Bayer Defends Aspirin Leadership While Eyeing Top OTC Spot
This article was originally published in The Tan Sheet
Executive Summary
Bayer boosted its marketing spend for aspirin during the third quarter in an effort to fend off competition in the cardio-aspirin category
You may also be interested in...
Aspirin Labeling Should Reflect Risk-Based CVD Prevention, Bayer Says
Aspirin therapy labeling should be revised to include an indication for primary prevention of myocardial infarction, reflecting a risk-based approach to cardiovascular disease prevention, Bayer maintains in a recent submission to FDA
Bayer Dealt Setback in Alka-Seltzer PPA Case
A jury award in favor of a plaintiff who used phenylpropanolamine-containing Alka-Seltzer may not bode well for Bayer in its ongoing PPA litigation
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC